Canoderm

Phase 3Small molecule

MMalmö University

Canoderm is one of 41 small molecule programs targeting Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentRecruiting

TreatmentPhase 3

Recruiting

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Canoderm

MMalmö University

Phase 3

1 2

Dexilant

Takeda

Preclinical

2 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Niclocide

Bayer

Preclinical

1 5

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 6

Valium

Akero Therapeutics

Preclinical

2 7

Clomid

Ferring

Preclinical

1 8

Aurlumyn

BBTG International Inc.

Preclinical

1 9

Lotemax

PPharmos

Preclinical

1 10

Norpramin

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

Treatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons with Diabetes

Recruiting·MMalmö University·Phase 4·NCT06427889·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Canoderm. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Canoderm compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Canoderm. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Malmö University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMalmö University

Canoderm

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

References

Drug Info

Quick Facts

Related News